Overview

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Assessment of effectiveness and local immune activation of Oncolytic Viruses H101 in patients with refractory malignant ascites.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University